Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial ...
The study is testing GLK-321, an eye drop drug, in several dose levels. It aims to lower signs and symptoms of Demodex blepharitis and could become a new product in Glaukos’ growing eye care pipeline ...
Q1 2026 Earnings Call April 29, 2026 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor ...
Glaukos Corporation GKOS reported a first-quarter 2026 adjusted loss of 18 cents per share, which came narrower than the ...
The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results